ORAVIG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORAVIG (ORAVIG).
Miconazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways; negligible systemic absorption after buccal administration. |
| Excretion | Primarily fecal (approximately 52%) with 39% of the dose recovered in urine; less than 0.5% of the dose is excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 24 hours, supporting once-daily buccal administration for sustained local oropharyngeal concentrations. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 4.0 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Systemic bioavailability is approximately 25% after buccal administration due to first-pass metabolism and local retention; absorption is primarily buccal. |
| Onset of Action | Within 2–4 hours after buccal application, measurable salivary concentrations; clinical antifungal effect observed within 24 hours. |
| Duration of Action | Therapeutic local concentrations persist for at least 24 hours after a single buccal tablet application, allowing once-daily dosing. |
| Molecular Weight | 416.13 |
ORAVIG (miconazole) 50 mg buccal tablet applied once daily to the upper gum region (canine fossa) for 14 consecutive days. The tablet is placed with the rounded side against the gum and held in place for 30 seconds to ensure adhesion.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment; the systemic absorption is minimal (1-2%) and miconazole is primarily hepatically metabolized with less than 1% excreted renally as unchanged drug. |
| Liver impairment | No specific dosing recommendations for hepatic impairment; caution is advised in severe hepatic dysfunction due to potential for increased systemic exposure, though clinical significance is unknown given minimal absorption. |
| Pediatric use | Safety and efficacy in pediatric patients below 16 years of age have not been established; no recommended dosing. |
| Geriatric use | No specific dose adjustment required in elderly patients; clinical studies included patients aged 65 and older with no overall differences in safety or effectiveness, but caution is advised due to potential age-related mucosal changes or concomitant medications. |
| 1st trimester | Avoid use due to potential teratogenicity; animal studies show fetal harm. |
| 2nd trimester | Use only if clearly needed; risk of fetal harm cannot be excluded. |
| 3rd trimester | Avoid near term due to risk of neonatal candidiasis and possible oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for ORAVIG (ORAVIG).
| Placental transfer | Systemic absorption is low; however, miconazole crosses placenta in animal studies. Human data limited. |
| Breastfeeding | Systemic absorption after topical buccal application is minimal but possible. Consider alternative antifungal due to theoretical risk of infant oral colonization. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to miconazole or any excipientSevere hepatic impairment
| Precautions | Hypersensitivity reactions including urticaria, pruritus, and angioedema., Local irritation, edema, or blistering at application site., Risk of aspiration if tablet not properly placed on gum., Avoid use in patients with severe hepatic impairment., Not for systemic fungal infections. |
| Food/Dietary | Avoid eating or drinking for at least 1 hour after applying the tablet. No specific food interactions known, but acidic or hot foods may dissolve the tablet faster, reducing efficacy. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, miconazole (the active ingredient) administered orally at doses up to 200 mg/kg/day (approximately 5 times the human dose based on body surface area) showed embryotoxicity and fetotoxicity. Risk cannot be ruled out. Use only if potential benefit justifies potential risk to the fetus. First trimester: avoid unless essential. Second and third trimesters: limited data, caution advised. |
| Fetal Monitoring | Monitor for signs of hepatotoxicity (elevated liver enzymes, jaundice) and allergic reactions. In pregnant women, fetal monitoring may include ultrasound to assess fetal growth if prolonged use. No specific maternal-fetal monitoring required for short-term topical buccal use. However, due to systemic absorption, periodic liver function tests may be considered in pregnant patients with hepatic impairment. |
| Fertility Effects | No specific studies on fertility in humans. In animal studies, miconazole did not impair fertility in rats at oral doses up to 200 mg/kg/day. However, high doses may cause hormonal disturbances. No known effect on human fertility with buccal administration. |
| ORAVIG (miconazole buccal tablet) is indicated for oropharyngeal candidiasis. Apply the tablet to the upper gum above the incisor tooth once daily for 14 days. Ensure the gum is dry before application. The tablet adheres to the mucosa and releases miconazole over time. Avoid chewing or swallowing whole. Monitor for hypersensitivity, especially in patients allergic to miconazole or other azoles. Use caution in patients with liver dysfunction due to potential hepatotoxicity. |
| Patient Advice | Apply the tablet to your upper gum above your front tooth each morning after brushing your teeth. · Dry the gum area with a clean tissue before applying the tablet. · Hold the tablet in place for 30 seconds to ensure adhesion. It will slowly dissolve over the day. · Do not chew, crush, or swallow the tablet whole. · Do not eat or drink for at least 1 hour after application to allow the tablet to adhere. · Remove the tablet if it causes irritation or if you need to remove it for any reason. · Complete the full 14-day course even if symptoms improve. · Contact your healthcare provider if you experience signs of allergy, such as rash, itching, or difficulty breathing. · Inform your doctor if you have liver problems or are taking blood thinners like warfarin. |